CN101596295B - Medicinal composition for treating gout and preparation process thereof - Google Patents
Medicinal composition for treating gout and preparation process thereof Download PDFInfo
- Publication number
- CN101596295B CN101596295B CN2009101487818A CN200910148781A CN101596295B CN 101596295 B CN101596295 B CN 101596295B CN 2009101487818 A CN2009101487818 A CN 2009101487818A CN 200910148781 A CN200910148781 A CN 200910148781A CN 101596295 B CN101596295 B CN 101596295B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- poria
- thick paste
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating gout and a preparation process thereof, which belong to the field of Chinese medicaments. The medicinal composition is prepared from raw materials of chinaroot greenbrier rhizome, deep-fried atractylodes macrocephala koidz, radix bupleuri, radix paeoniae rubra, Chinese angelica, fructus chaenomelis, deep-dried coix seed, deep-dried cortex phellodendri, radix achyranthis bidentatae and liquorice, and can be prepared into tablets, capsules, granules, pills and other formulations according to the requirements. The medicinal composition has obvious effect of treating or preventing hyperuricemia and gout diseases.
Description
Technical field
The present invention relates to a kind of is pharmaceutical composition of effective ingredient and its production and use by Chinese medicine or natural plants, and particularly relating to a kind of is the treatment of feedstock production one-tenth or the medicine of prevention hyperuricemia and gout with Poria, Rhizoma Atractylodis Macrocephalae preparata, HERBA BUPLEURL, Radix Paeoniae Rubra, Radix Angelicae Sinensis, Fructus Chaenomelis, burnt Semen Coicis, charred Cortex Phellodendri, Radix Achyranthis Bidentatae, Radix Glycyrrhizae.Belong to the field of Chinese medicines.
Background technology
Gout is to cause purine metabolism obstacle and blood uric acid to continue to raise and the disease that causes by the heritability or the acquired cause of disease.Clinically with hyperuricemia companion gouty acute arthritis show effect repeatedly, solid lesion such as tophus deposition, gouty chronic arthritis and joint deformity, glomerule and renal tubules and urate calculus form characteristics.The primary disease course of disease is very long, later stage Chang Bingfa renal failure, arteriosclerosis, coronary heart disease, cerebrovascular accident etc.Gout is one of the most ancient human metabolic disease, also is the worldwide disease that spreads all over the world.In China, along with the continuous variation of people's work and life style and dietary structure, the morbidity patient number of hyperuricemia and gout increases year by year.
Modern medicine is generally undertaken by acute stages treated, intermission and chronic phase treatment the treatment of gout; wherein acute stages treated mainly is the outbreak that stops acute arthritis quickly and effectively; reduce uricopoiesis; promote urate excretion; intermission and chronic phase treatment mainly are to control blood uric acid at normal level, the organ function that control and protection have injured.At present the drug main of clinical gout commonly used will be based on colchicine, nonsteroidal antiinflammatory drug, hormone, promotion urate excretion medicine (as probenecid, sulphur than ketone and benzbromarone) and inhibition uric acid synthetic drug (allopurinol), acute period of disease is mainly used colchicine, nonsteroidal antiinflammatory drug, hormone, and intermission and chronic phase are mainly used and promote urate excretion medicine, inhibition uric acid synthetic drug.Yet these medicines all have certain toxic and side effects in treatment, and these become the bottleneck of its clinical practice.The safe and effective medicine of the gout that seeks treatment from Chinese medicine and preparation are a kind of trend, also meet the needs of clinical diagnosis and treatment.
Summary of the invention
Goal of the invention:
The purpose of this invention is to provide a kind of pharmaceutical composition that is prepared into by Poria, the Rhizoma Atractylodis Macrocephalae, Radix Bupleuri, Radix Paeoniae Rubra, Radix Angelicae Sinensis, Fructus Chaenomelis, Semen Coicis, Cortex Phellodendri, Radix Achyranthis Bidentatae, Radix Glycyrrhizae, this pharmaceutical composition is used to treatment or prevention hyperuricemia and gout.The present invention provides this preparation of drug combination method simultaneously.
Technical scheme:
The invention provides a kind of pharmaceutical composition that is used for the treatment of gout, the effective ingredient of this pharmaceutical composition is to be made by the crude drug of following weight ratio:
7～13 parts in Poria, 7～13 parts of the Rhizoma Atractylodis Macrocephalaes, 7～13 parts of Radix Angelicae Sinensis, 7～13 parts of Semen Coiciss, 7～13 parts of Radix Achyranthis Bidentataes, 7～13 parts of Radix Paeoniae Rubra, 4～8 parts of Fructus Chaenomeliss, 4～8 parts of Cortex Phellodendris, 4～8 parts of Radix Bupleuri, 4～8 parts in Radix Glycyrrhizae.
The above-mentioned raw materials medicine can have following several preferred proportioning mode:
Proportioning one: 10 parts in Poria, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Angelicae Sinensis, 10 parts of Semen Coiciss, 10 parts of Radix Achyranthis Bidentataes, 9 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 5 parts of Radix Bupleuri, 5 parts in Radix Glycyrrhizae.
Proportioning two: 10 parts in Poria, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 9 parts of Radix Angelicae Sinensis, 9 parts of Semen Coiciss, 8 parts of Radix Achyranthis Bidentataes, 8 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 6 parts of Radix Bupleuri, 6 parts in Radix Glycyrrhizae.
Proportioning three: 11 parts in Poria, 11 parts of the Rhizoma Atractylodis Macrocephalaes, 11 parts of Radix Angelicae Sinensis, 9 parts of Semen Coiciss, 9 parts of Radix Achyranthis Bidentataes, 8 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 6 parts of Radix Bupleuri, 5 parts in Radix Glycyrrhizae.
Further preferred, the Poria in the above-mentioned raw materials medicine, the Rhizoma Atractylodis Macrocephalae, Semen Coicis, Radix Achyranthis Bidentatae, Cortex Phellodendri and Radix Bupleuri can use Poria, Rhizoma Atractylodis Macrocephalae preparata, burnt Semen Coicis, Radix Achyranthis Bidentatae, charred Cortex Phellodendri and HERBA BUPLEURL to replace respectively.
More than each crude drug should meet the officinal relevant regulations of China national, specifically:
Poria: be the dry sclerotia of Polyporaceae fungus Poria Poria cocos (Schw.) Wolf; Wherein, Poria is meant the part of Poria inner white densification.
The Rhizoma Atractylodis Macrocephalae: be the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz..The processed with honey wheat bran is sprinkled in the heat pot, adds Rhizoma Atractylodis Macrocephalae sheet when waiting to smolder, fry to coke yellow, effusion burnt odor gas, take out, sieve removes the processed with honey wheat bran, promptly gets Rhizoma Atractylodis Macrocephalae preparata.
Radix Angelicae Sinensis: be the dry root of umbelliferae angelica Angelica sinensis (Oliv.) Diels.
Semen Coicis: be the dry mature kernal of grass Semen Coicis Coix lacryma-jobi L.var.ma-yuen (Roman.) Stapf.Wheat bran is sprinkling upon in the heat pot, is heated to when smoldering, put into the clean medical material of Semen Coicis, stir rapidly, fry when the Semen Coicis surface is yellow, take out, sieve removes wheat bran, cools, and promptly gets burnt Semen Coicis (being also referred to as burnt Semen Coicis).
Radix Achyranthis Bidentatae: be the dry root of amaranthaceous plant Radix Achyranthis Bidentatae Achyranthes bidentata BL..Chinese medicine genuine medicinal materials " Radix Achyranthis Bidentatae " best results of producing wherein with Henan Province.
Radix Paeoniae Rubra: be the dry root of ranunculaceae plant Radix Paeoniae Paeonia lactiflora Pall. or river Radix Paeoniae Rubra Paeonia veitchii Lynch.
Fructus Chaenomelis: be the dry almost ripe fruit of rosaceous plant chaenomeles lagenaria Chaenomeles speciosa (Sweet) Nakai.
Cortex Phellodendri: be the dry bark of rutaceae wampee Phellodendron chinense Schneid. or Cortex Phellodendri Phellodendronamurense Rupr..The Cortex Phellodendri medical material is put in the heat pot, when frying with high heat to surperficial coke black, inner coke yellow, the spray clear water a little, extinguish Mars, take out, dry, promptly get charred Cortex Phellodendri (being also referred to as the Cortex Phellodendri charcoal).
Radix Bupleuri: be dry root or the herb of umbelliferae bupleurum Bupleurum chinense DC. or Radix Bupeuri Scorzonerfolii. Bupleurumscorzonerifolium Willd..Wherein, the young tender Radix Bupleuri herb of gathering spring is called HERBA BUPLEURL.
Radix Glycyrrhizae: be the dry root and rhizome of glycyrrhizic legume Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. Glycyrrhiza inflataBat. or Glycyrrhiza glabra L. Glycyrrhiza glabra L..
Pharmaceutical composition of the present invention can use in many ways, takes as directly decocting with water into decoction; Or after extracting processing, make various oral formulations, comprise tablet, hard capsule, soft capsule, granule, pill and oral liquid etc.The inventor provides this preparation of drug combination method simultaneously, comprises the steps:
A, get crude drug, wherein Poria powder is broken into fine powder, standby;
B, other nine flavors Chinese medicine merge is mixed,, use 6～12 times of amounts at every turn with 60%～80% alcohol reflux 1～3 time, reflux, extract, 1～2 hour, ethanol is reclaimed in extracting liquid filtering, merging, relative density was 1.10～1.25 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
Medicinal residues reuse water boiling and extraction behind c, the ethanol extraction 1～3 time is used 8～12 times of water gagings at every turn, and boil and extracted 1～2 hour, extracting liquid filtering, merging, relative density was 1.10～1.25 thick paste when vacuum concentration became 65 ℃, and is standby;
D, combining step b, c gained thick paste, in the Poria fine powder adding thick paste with step a, fully mixing is made extractum, and oven dry is pulverized, and makes required preparation.
Specifically, as make capsule, then by following processing step:
A, get crude drug, Poria powder is broken into 80 order fine powders, standby;
B, other nine flavors Chinese medicine merge is mixed, be ground into coarse powder, with 70% alcohol reflux three times, at every turn with 10 times of amounts, reflux, extract, 2 hours, extracting liquid filtering, merging, reclaim ethanol, relative density was 1.20 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
Medicinal residues reuse water boiling and extraction behind c, the ethanol extraction three times is used 10 times of water gagings at every turn, and boil and extracted 1.5 hours, extracting liquid filtering, merging, relative density was 1.20 thick paste when vacuum concentration became 65 ℃, and is standby;
D, combining step b, c gained thick paste, in the Poria fine powder adding thick paste with step a, fully mixing is made extractum, and oven dry is ground into 60 order fine powders, granulates with 70% ethanol, 40 mesh sieves, drying, encapsulated.
Beneficial effect:
Pharmaceutical composition of the present invention has significant effect aspect treatment hyperuricemia and the gout, and the inventor has proved the existence of this effect by following zoopery.
Experimental example one, pharmaceutical composition of the present invention are to the influence of hyperuricemia mice serum uric acid level
1 material
1.1 the animal Kunming mouse is male, body weight (20 ± 2) g, and unming Medical College's Experimental Animal Center provides, the quality certification number 0002689.Before using laboratory rearing 1 day to adapt to animal housing's condition.In whole experiment, freely drink water and subsist.
1.2 instrument and reagent Olympus AU 600 type full-automatic biochemical detectors; Allopurinol (Qingyang, Chongqing pharmaceutcal corporation, Ltd, 070503); Oxonic acid potassium salt (Oxonic acid potassium salt) is Aldrich Chemical Company product.Other are homemade analytical reagent.
1.3 medicine pharmaceutical composition of the present invention (lot number: 20060516) provide, as follows preparation by Tianxiu Plant Sci-Tech Development Co., Ltd., Yunnan.
Prescription: the burnt Semen Coicis 1000g of Poria 1000g Rhizoma Atractylodis Macrocephalae preparata 1000g Radix Angelicae Sinensis 1000g
Radix Achyranthis Bidentatae 1000g Radix Paeoniae Rubra 900g Fructus Chaenomelis 600g charred Cortex Phellodendri 600g
HERBA BUPLEURL 500g Radix Glycyrrhizae 500g
Preparation technology:
[1] Poria powder is broken into 80 order fine powders, standby;
[2] other nine flavors Chinese medicine is merged mixing, be ground into coarse powder; With 70% alcohol reflux nine flavor Chinese medicine coarse powder, extracts three times, measure 70% ethanol (V/W) with 10 times at every turn, reflux, extract, 2 hours, extracting liquid filtering, merging, recovery ethanol, vacuum concentration become thick paste (65 ℃ time relative density 1.2), and is standby;
[3] extract the nine flavor Chinese medicine coarse powder that ethanol extraction is crossed with water boil, extracts three times, use 10 times of water gagings (V/W) at every turn, boil extraction 1.5 hours, extracting liquid filtering, merging, vacuum concentration becomes thick paste (65 ℃ time relative density 1.2), and is standby;
[4] merge ethanol extraction and water extraction thick paste, the Poria fine powder is added in the thick paste, fully mixing is made extractum, and oven dry is ground into fine powder, and is standby.
Use 0.8% sodium carboxymethyl cellulose (CMC-Na) to prepare the suspension of debita spissitudo respectively said medicine extract fine powder, allopurinol, standby.
2 methods
2.1 it is uricase inhibitor that oxonic acid potassium salt is selected in the foundation of hyperuricemia model for use, suppresses uricase, increases serum uric acid level, causes the mice hyperuricemia model.Measure serum uric acid with Olympus AU 600 type full-automatic biochemical detectors.
2.2 experiment grouping and administration male mice divide into groups 12 every group at random.Experiment is divided into blank group, the basic, normal, high dosage group of compositions and positive control drug allopurinol group, model group.Blank group and model group every day are all by 10mLkg
-1Dosage ig0.4% sodium carboxymethyl cellulose (CMC-Na) is 4d continuously.Medicine group ig every day administration 1 time, continuous 4d, the basic, normal, high dosage of medicine of the present invention are respectively 1000,2000,4000mgkg
-1, allopurinol dosage is 10mgkg
-1, 1h before 1 administration in the end, model group, medicine group, positive drug group ip oxygen acid piperazine potassium salt 300mgkg
-1, to take a blood sample from the mouse orbit rear vein beard behind the administration 1h, blood sample places the centrifuge tube of 1.5mL respectively, and at room temperature natural blood coagulation 1h is at 2500rmin
-1Centrifugal 5min.Every part of blood sample is got 200 μ L serum and is used for testing uric acid.
2.3 statistics is carried out the variance analysis check with result.
3 results
3.1 pharmaceutical composition of the present invention the results are shown in Table 1 to the influence of hyperuricemia mice serum uric acid level.Compare with model group, the middle dosage group of medicine reduces hyperuricemia mice serum uric acid level significantly, and high dose group reduces hyperuricemia mice serum uric acid level very significantly.
3.2 allopurinol can be reduced to hyperuricemia mice serum uric acid level below the normal value.
The above results prompting pharmaceutical composition of the present invention has the obvious treatment effect to hyperuricemia.
Table 1 blood uric acid index (n=12)
| Group | Dosage/mgkg -1 | Serum uric acid level/μ molL -1 |
| Blank group | - | 63.58±18.37 |
| Model group | - | 207.67±62.15 |
| Medicine low dosage of the present invention | 1000 | 170.00±48.55 |
| Dosage in the medicine of the present invention | 2000 | 158.75±49.18 * |
| Medicine high dose of the present invention | 4000 | 135.42±50.43 ** |
| Allopurinol | 10 | 18.17±15.12 ** |
Annotate: compare with model group
*P＜0.05,
*P＜0.01
The influence of experimental example two, pharmaceutical composition Dichlorodiphenyl Acetate induced mice writhing response of the present invention
1, material
1.1 animal is with experimental example one.
1.2 medicine and reagent
Test sample: get the embodiment of the invention 2 and embodiment 10 gained preparation extracts respectively, be made into desired concn as required, respectively as treatment group 1 and treatment group 2.
Positive control drug: get aspirin 2g, add the solution that water is made 100ml.
Reagent: 0.6% acetum.
2, method and result
2.1 test method is got 40 of mices, male and female half and half, body weight 20 ± 2g, evenly be divided into 4 groups at random, every group 10, promptly blank group, treatment group 1, treatment group 2, positive drug group, gastric infusion dosage is 2g/kg, blank group filling stomach gives the normal saline with volume, administration every day 1 time, successive administration 5 days, 1h after last 1 administration, 0.6% acetum of the new preparation of every Mus lumbar injection is observed incubation period and the interior mouse writhing generation number of 10min that writhing response appears in mice first immediately.
2.2 result of the test the results are shown in Table 2.
The influence (n=10) of table 2 Dichlorodiphenyl Acetate induced mice writhing response
| Group | Take place the incubation period (min) of writhing response first | Turn round body frequency (inferior) in the 10min |
| Treatment group 1 | 4.38±0.95 ** | 10.5±3.0 ** |
| Treatment group 2 | 4.69±0.27 ** | 11.6±2.8 ** |
| The positive drug group | 4.55±0.64 ** | 10.1±3.6 ** |
| The blank group | 3.32±0.88 | 19.6±4.2 |
Annotate: with blank group ratio,
*P＜0.05,
*P＜0.01.
Above result of the test shows that positive drug group and 2 treatment groups all can obviously prolong the incubation period that mice is turned round body first, reduces the mouse writhing number of times, relatively has utmost point significant difference with the blank group.
Experimental example three, pharmaceutical composition of the present invention are to the bullate influence of uric acid sodium inducing mouse foot
1, material
1.1 animal is with experimental example one.
1.2 medicine and reagent
Test sample: with experimental example 2.
Positive control drug: get colchicine 6g, add the solution that water is made 100ml.
Reagent: uric acid sodium.
2, method and result
2.1 test method is got test and is used 50 of mices, be divided into 5 groups at random, every group 10: blank group, treatment group 1, treatment group 2, positive drug group, every day, gastric infusion was 1 time, dosage is 2g/kg, successive administration 4 days, after film time administration 30 minutes, at the right back sufficient pad subcutaneous injection uric acid sodium normal saline suspension 0.05ml of portion, induce the generation of gouty arthritis, respectively cause scorching before and cause scorching back 2,4,6 hours, survey with projector (amplifying 6 times) and cause 0.5cm place diameter under the scorching limb ankle joint, consequently the difference of inflammation front and back is made the arthritic swelling degree of gouty.
2.2 result of the test the results are shown in Table 3.
Table 3 pair uric acid sodium inducing mouse foot bullate influence (n=10)
Annotate: with blank group ratio,
*P＜0.05,
*P＜0.01.
Above result of the test shows, 2 treatment groups and positive drug group all can obviously reduce uric acid sodium and cause scorching back foot swelling degree, relatively have utmost point significant difference with the blank group.
Above-mentioned experimental result prompting, pharmaceutical composition of the present invention has notable therapeutic effect for gout.
Experimental example four, pharmaceutical composition its mouse oral of the present invention acute toxicity test
1. make a summary: this experiment adopts the ICR mice that compositions is carried out its mouse oral maximal dose administration acute toxicity test.Do not see any untoward reaction after the administration.Its measurement result: MTD is 8.0gkg
-1Body weight.
2. experiment purpose: observe being subjected to the once heavy dose of acute toxicity and the death condition that are produced behind the animal of giving of reagent thing.
3. material:
A) be subjected to the reagent thing: with experimental example 1.
B) laboratory animal: the ICR mice is provided the animal quality certification number 0002685 by unming Medical College's animal center.
4. method: selecting body weight is 20 of the healthy ICR mices of 18-22g, male and female half and half.Take by weighing compositions 4g, add 0.4%CMC-Na to 5ML, press 0.1mL/10g body weight gastric infusion, observed 7 days continuously after the administration, the record animal poisons and death condition.
5. result: after 20 mouse stomach administrations, feed drinking-water is normal.Continuous observation in 7 days does not see that any untoward reaction appears in animal, all animals survival, and ordinary circumstance is good, and appetite is normal.It is 8gkg that the result records compositions its mouse oral MTD
-1Body weight.(calculate the maximal dose 0.072gkg that is equivalent to clinical recommendation according to the 50kg body weight
-1/ day 111 times)
6. estimate: this research is carried out its mouse oral mtd test with compositions.Its MTD is 8gkg
-1/ body weight, prompting compositions its mouse oral LD
50Greater than 8gkg
-1Body weight has higher safety.
Below all embodiment gained medicine compositions the experiment proved that all have above-mentioned therapeutic effect and higher clinical safety in utilization.
The specific embodiment
Embodiment 1:
Crude drug: Poria 10kg, Rhizoma Atractylodis Macrocephalae 10kg, Radix Angelicae Sinensis 10kg, Semen Coicis 10kg, Radix Achyranthis Bidentatae 10kg, Radix Paeoniae Rubra 9kg, Fructus Chaenomelis 6kg, Cortex Phellodendri 6kg, Radix Bupleuri 5kg, Radix Glycyrrhizae 5kg.
Technology:
(1) get crude drug, wherein Poria powder is broken into fine powder, standby;
(2) other nine flavors Chinese medicine merge is mixed,, use 12 times of amounts at every turn with 80% alcohol reflux 3 times, reflux, extract, 2 hours, extracting liquid filtering, merging, recovery ethanol, relative density was 1.25 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
(3) the medicinal residues reuse water boiling and extraction behind the ethanol extraction is 3 times, uses 12 times of water gagings at every turn, and boil and extracted 2 hours, extracting liquid filtering, merging, relative density was 1.25 thick paste when vacuum concentration became 65 ℃, and is standby;
(4) combining step (2) (3) gained thick paste, in the Poria fine powder adding thick paste with step (1), fully mixing is made extractum, and oven dry is pulverized, and adds appropriate amount of starch and microcrystalline Cellulose, is pressed into tablet.
Embodiment 2:
Crude drug: Poria 10kg, Rhizoma Atractylodis Macrocephalae 10kg, Radix Angelicae Sinensis 9kg, Semen Coicis 9kg, Radix Achyranthis Bidentatae 8kg, Radix Paeoniae Rubra 8kg, Fructus Chaenomelis 6kg, Cortex Phellodendri 6kg, Radix Bupleuri 6kg, Radix Glycyrrhizae 6kg.
Technology:
(1) get crude drug, wherein Poria powder is broken into fine powder, standby;
(2) other nine flavors Chinese medicine merge is mixed, with 6 times of amount 60% alcohol reflux 1 hour, extracting liquid filtering, recovery ethanol, relative density was 1.10 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
(3) medicinal residues behind the ethanol extraction add 8 times of water gagings again and boil and extracted 1 hour, and relative density was 1.10 thick paste when extracting liquid filtering, vacuum concentration became 65 ℃, and is standby;
(4) combining step (2) (3) gained thick paste, in the Poria fine powder adding thick paste with step (1), fully mixing is made extractum, and oven dry is pulverized, and adds starch and dextrin, with 70% alcohol granulation, makes granule.
Embodiment 3:
Crude drug: Poria 11kg, Rhizoma Atractylodis Macrocephalae 11kg, Radix Angelicae Sinensis 11kg, Semen Coicis 9kg, Radix Achyranthis Bidentatae 9kg, Radix Paeoniae Rubra 8kg, Fructus Chaenomelis 6kg, Cortex Phellodendri 6kg, Radix Bupleuri 6kg, Radix Glycyrrhizae 5kg.
Technology:
(1) get crude drug, wherein Poria powder is broken into 60 order fine powders, standby;
(2) other nine flavors Chinese medicine merge is mixed,, use 6 times of amounts at every turn with 80% alcohol reflux 2 times, reflux, extract, 1 hour, extracting liquid filtering, merging, recovery ethanol, relative density was 1.15 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
(3) the medicinal residues reuse water boiling and extraction behind the ethanol extraction is 2 times, uses 12 times of water gagings at every turn, and boil and extracted 1.5 hours, extracting liquid filtering, merging, relative density was 1.15 thick paste when vacuum concentration became 65 ℃, and is standby;
(4) combining step (2) (3) gained thick paste, in the Poria fine powder adding thick paste with step (1), fully mixing is made extractum, and oven dry is pulverized, and grinds altogether evenly with the capacity soybean oil, is pressed into soft capsule.
Embodiment 4:
Crude drug: Poria 13kg, Rhizoma Atractylodis Macrocephalae 13kg, Radix Angelicae Sinensis 13kg, Semen Coicis 13kg, Radix Achyranthis Bidentatae 7kg, Radix Paeoniae Rubra 7kg, Fructus Chaenomelis 4kg, Cortex Phellodendri 4kg, Radix Bupleuri 8kg, Radix Glycyrrhizae 8kg.
Technology:
(1) get crude drug, Poria powder is broken into 80 order fine powders, standby;
(2) other nine flavors Chinese medicine merge is mixed, be ground into coarse powder, with 70% alcohol reflux three times, at every turn with 10 times of amounts, reflux, extract, 2 hours, extracting liquid filtering, merging, reclaim ethanol, relative density was 1.20 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
(3) the medicinal residues reuse water boiling and extraction behind the ethanol extraction is three times, uses 10 times of water gagings at every turn, and boil and extracted 1.5 hours, extracting liquid filtering, merging, relative density was 1.20 thick paste when vacuum concentration became 65 ℃, and is standby;
(4) combining step (2) (3) gained thick paste, in the Poria fine powder adding thick paste with step (1), fully mixing is made extractum, and oven dry is ground into 60 order fine powders, granulates with 70% ethanol, 40 mesh sieves, and drying is dressed up hard capsule.
Embodiment 5:
Crude drug: Poria 7kg, Rhizoma Atractylodis Macrocephalae 7kg, Radix Angelicae Sinensis 7kg, Semen Coicis 7kg, Radix Achyranthis Bidentatae 13kg, Radix Paeoniae Rubra 13kg, Fructus Chaenomelis 8kg, Cortex Phellodendri 8kg, Radix Bupleuri 4kg, Radix Glycyrrhizae 4kg.
Technology:
(1) get crude drug, wherein Poria powder is broken into fine powder, standby;
(2) other nine flavors Chinese medicine merge is mixed,, use 10 times of amounts at every turn with 65% alcohol reflux 3 times, reflux, extract, 1.5 hours, extracting liquid filtering, merging, recovery ethanol, relative density was 1.15 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
(3) the medicinal residues reuse water boiling and extraction behind the ethanol extraction is 2 times, uses 10 times of water gagings at every turn, and boil and extracted 1 hour, extracting liquid filtering, merging, relative density was 1.15 thick paste when vacuum concentration became 65 ℃, and is standby;
(4) combining step (2) (3) gained thick paste, in the Poria fine powder adding thick paste with step (1), fully mixing is made extractum, and oven dry is pulverized, and is mixed with starch, and the system soft material is made pill.
Embodiment 6:
Crude drug: Poria 10kg, Rhizoma Atractylodis Macrocephalae preparata 10kg, Radix Angelicae Sinensis 10kg, burnt Semen Coicis 10kg, Radix Achyranthis Bidentatae 10kg, Radix Paeoniae Rubra 9kg, Fructus Chaenomelis 6kg, charred Cortex Phellodendri 6kg, HERBA BUPLEURL 5kg, Radix Glycyrrhizae 5kg.
Technology: with embodiment 5.
Embodiment 7:
Crude drug: Poria 10kg, Rhizoma Atractylodis Macrocephalae preparata 10kg, Radix Angelicae Sinensis 9kg, burnt Semen Coicis 9kg, Radix Achyranthis Bidentatae 8kg, Radix Paeoniae Rubra 8kg, Fructus Chaenomelis 6kg, charred Cortex Phellodendri 6kg, HERBA BUPLEURL 6kg, Radix Glycyrrhizae 6kg.
Technology: with embodiment 4.
Embodiment 8:
Crude drug: Poria 11kg, Rhizoma Atractylodis Macrocephalae preparata 11kg, Radix Angelicae Sinensis 11kg, burnt Semen Coicis 9kg, Radix Achyranthis Bidentatae 9kg, Radix Paeoniae Rubra 8kg, Fructus Chaenomelis 6kg, charred Cortex Phellodendri 6kg, HERBA BUPLEURL 6kg, Radix Glycyrrhizae 5kg.
Technology: with embodiment 3.
Embodiment 9:
Crude drug: Poria 13kg, Rhizoma Atractylodis Macrocephalae preparata 13kg, Radix Angelicae Sinensis 13kg, burnt Semen Coicis 13kg, Radix Achyranthis Bidentatae 7kg, Radix Paeoniae Rubra 7kg, Fructus Chaenomelis 4kg, charred Cortex Phellodendri 8kg, HERBA BUPLEURL 8kg, Radix Glycyrrhizae 8kg.
Technology: with embodiment 2.
Embodiment 10:
Crude drug: Poria 7kg, Rhizoma Atractylodis Macrocephalae preparata 7kg, Radix Angelicae Sinensis 7kg, burnt Semen Coicis 7kg, Radix Achyranthis Bidentatae 13kg, Radix Paeoniae Rubra 13kg, Fructus Chaenomelis 8kg, charred Cortex Phellodendri 4kg, HERBA BUPLEURL 4kg, Radix Glycyrrhizae 4kg.
Technology: with embodiment 1.
Embodiment 11:
Crude drug: Poria 12kg, Rhizoma Atractylodis Macrocephalae 12kg, Radix Angelicae Sinensis 12kg, Semen Coicis 12kg, Radix Achyranthis Bidentatae 12kg, Radix Paeoniae Rubra 10kg, Fructus Chaenomelis 8kg, Cortex Phellodendri 8kg, Radix Bupleuri 6kg, Radix Glycyrrhizae 6kg.
Technology: the above-mentioned raw materials medicine is added 10 times of water gagings decocted 1.5 hours, filter; Medicinal residues add 8 times of water gagings and decocted 1 hour, filter; Merging filtrate gets medicinal liquid and gets final product.
Embodiment 12: Poria 7kg, Rhizoma Atractylodis Macrocephalae 7kg, Radix Angelicae Sinensis 13kg, Semen Coicis 13kg, Radix Achyranthis Bidentatae 13kg, Radix Paeoniae Rubra 6kg, Fructus Chaenomelis 6kg, Cortex Phellodendri 6kg, Radix Bupleuri 4kg, Radix Glycyrrhizae 4kg.
Technology: the above-mentioned raw materials medicine with 60% ethanol extraction three times, is added 12 times of amounts for the first time and extracted 1.5 hours, add 10 times of amounts for the second time and extracted 1 hour, add 10 times for the third time and extracted 1 hour; Merge extractive liquid,, decompression recycling ethanol filters; The filtrate thin up is to desired concn, and filtration, packing, sterilization promptly get oral liquid.
Claims (8)
1. pharmaceutical composition that is used for the treatment of gout, the effective ingredient that it is characterized in that this pharmaceutical composition is to be made by the crude drug of following weight ratio:
7～13 parts in Poria, 7～13 parts of the Rhizoma Atractylodis Macrocephalaes, 7～13 parts of Radix Angelicae Sinensis, 7～13 parts of Semen Coiciss, 7～13 parts of Radix Achyranthis Bidentataes,
7～13 parts of Radix Paeoniae Rubra, 4～8 parts of Fructus Chaenomeliss, 4～8 parts of Cortex Phellodendris, 4～8 parts of Radix Bupleuri, 4～8 parts in Radix Glycyrrhizae.
2. pharmaceutical composition according to claim 1 is characterized in that the weight ratio of each crude drug is:
10 parts in Poria, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Angelicae Sinensis, 10 parts of Semen Coiciss, 10 parts of Radix Achyranthis Bidentataes,
9 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 5 parts of Radix Bupleuri, 5 parts in Radix Glycyrrhizae.
3. pharmaceutical composition according to claim 1 is characterized in that the weight ratio of each crude drug is:
10 parts in Poria, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 9 parts of Radix Angelicae Sinensis, 9 parts of Semen Coiciss, 8 parts of Radix Achyranthis Bidentataes,
8 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 6 parts of Radix Bupleuri, 6 parts in Radix Glycyrrhizae.
4. pharmaceutical composition according to claim 1 is characterized in that the weight ratio of each crude drug is:
11 parts in Poria, 11 parts of the Rhizoma Atractylodis Macrocephalaes, 11 parts of Radix Angelicae Sinensis, 9 parts of Semen Coiciss, 9 parts of Radix Achyranthis Bidentataes,
8 parts of Radix Paeoniae Rubra, 6 parts of Fructus Chaenomeliss, 6 parts of Cortex Phellodendris, 6 parts of Radix Bupleuri, 5 parts in Radix Glycyrrhizae.
5. according to arbitrary described pharmaceutical composition in the claim 1 to 4, it is characterized in that described Poria, the Rhizoma Atractylodis Macrocephalae, Semen Coicis, Radix Achyranthis Bidentatae, Cortex Phellodendri and Radix Bupleuri are respectively Poria, Rhizoma Atractylodis Macrocephalae preparata, burnt Semen Coicis, Radix Achyranthis Bidentatae, charred Cortex Phellodendri and HERBA BUPLEURL.
6. arbitrary described preparation of drug combination method in the claim 1 to 5 is characterized in that this method comprises the steps:
A, get crude drug, wherein Poria powder is broken into fine powder, standby;
B, other nine flavors Chinese medicine merge is mixed,, use 6～12 times of amounts at every turn with 60%～80% alcohol reflux 1～3 time, reflux, extract, 1～2 hour, ethanol is reclaimed in extracting liquid filtering, merging, relative density was 1.10～1.25 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
Medicinal residues reuse water boiling and extraction behind c, the ethanol extraction 1～3 time is used 8～12 times of water gagings at every turn, and boil and extracted 1～2 hour, extracting liquid filtering, merging, relative density was 1.10～1.25 thick paste when vacuum concentration became 65 ℃, and is standby;
D, combining step b, c gained thick paste, in the Poria fine powder adding thick paste with step a, fully mixing is made extractum, and oven dry is pulverized, and makes required preparation.
7. preparation method according to claim 6 is characterized in that the preparation process of capsule is:
A, get crude drug, Poria powder is broken into 80 order fine powders, standby;
B, other nine flavors Chinese medicine merge is mixed, be ground into coarse powder, with 70% alcohol reflux three times, at every turn with 10 times of amounts, reflux, extract, 2 hours, extracting liquid filtering, merging, reclaim ethanol, relative density was 1.20 thick paste when surplus liquid vacuum concentration became 65 ℃, and is standby;
Medicinal residues reuse water boiling and extraction behind c, the ethanol extraction three times is used 10 times of water gagings at every turn, and boil and extracted 1.5 hours, extracting liquid filtering, merging, relative density was 1.20 thick paste when vacuum concentration became 65 ℃, and is standby;
D, combining step b, c gained thick paste, in the Poria fine powder adding thick paste with step a, fully mixing is made extractum, and oven dry is ground into 60 order fine powders, granulates with 70% ethanol, 40 mesh sieves, drying, encapsulated.
8. arbitrary described pharmaceutical composition is used for the treatment of or prevents application in the medicine of hyperuricemia and/or gout in preparation in the claim 1 to 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101487818A CN101596295B (en) | 2009-07-03 | 2009-07-03 | Medicinal composition for treating gout and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101487818A CN101596295B (en) | 2009-07-03 | 2009-07-03 | Medicinal composition for treating gout and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101596295A CN101596295A (en) | 2009-12-09 |
| CN101596295B true CN101596295B (en) | 2011-03-23 |
Family
ID=41418014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101487818A Active CN101596295B (en) | 2009-07-03 | 2009-07-03 | Medicinal composition for treating gout and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101596295B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251852B (en) * | 2013-05-28 | 2016-01-13 | 陈金宗 | A kind of medicine coordinating super micro knife to treat osteoarthritis |
| CN103622019B (en) * | 2013-12-02 | 2015-08-19 | 广西健丰药业有限公司 | A kind of reducing blood lipid, anti-trioxypurine Chinese medicine composition |
| CN103948707B (en) * | 2014-05-27 | 2016-03-02 | 刘云杰 | A kind of Chinese medicine for the treatment of restless legs syndrome |
| CN103948708B (en) * | 2014-05-29 | 2015-08-19 | 张玉芳 | A kind of Chinese medicine for the treatment of restless legs syndrome |
| CN106266788A (en) * | 2016-09-29 | 2017-01-04 | 林峰 | A kind of treat the soothing the liver removing toxic substances of gouty arthritis, QiReLiShi herbs compositions |
| CN106511528B (en) * | 2016-10-14 | 2019-08-23 | 三峡大学 | A kind of wrinkled papaya extract, composition and purposes |
| CN107519427A (en) * | 2017-10-10 | 2017-12-29 | 李西平 | A kind of composition and its solid beverage and preparation method for being used to treat high lithemia |
| CN108324874B (en) * | 2018-05-08 | 2021-01-05 | 大连医科大学 | Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat |
| CN115364179B (en) * | 2022-08-29 | 2024-02-06 | 吉林省中医药科学院（吉林省中医药科学院第一临床医院） | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799620A (en) * | 2005-08-17 | 2006-07-12 | 王林祥 | Healthcare wine and its preparation method |
-
2009
- 2009-07-03 CN CN2009101487818A patent/CN101596295B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799620A (en) * | 2005-08-17 | 2006-07-12 | 王林祥 | Healthcare wine and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101596295A (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101596295B (en) | Medicinal composition for treating gout and preparation process thereof | |
| CN1286513C (en) | Chinese medicine composition for treating dermatosis and its preparing method | |
| SG188283A1 (en) | Pharmaceutical composition for treating insomnia and preparation method thereof | |
| CN113577230A (en) | Composition for preventing and delaying occurrence and development of senile dementia and application thereof | |
| CN101485870A (en) | Medicament for promoting digestion and expelling intestinal parasites | |
| CN104398841A (en) | Traditional Chinese medicine preparation for treating cataract and glaucoma and preparation method of traditional Chinese medicine preparation | |
| CN100469377C (en) | Nankang soft capsule for treating prostatitis | |
| CN101347605B (en) | Chinese medicinal composition for treating gout and preparation method and application thereof | |
| CN104127823A (en) | Traditional Chinese medicine composition for treating infantile malnutrition and anorexia and preparation thereof | |
| CN115350256B (en) | Traditional Chinese medicine composition for treating insomnia and preparation method thereof | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
| CN102552806A (en) | Fat-burning dredging particles and preparation method thereof | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN101129748B (en) | Proprietary Chinese medicine for treating cancer of the lungs and method of preparing the same | |
| CN106309736A (en) | Anti-fatigue traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN104887968A (en) | Traditional Chinese medicine preparation for preventing contrast associated nephropathy as well as preparation method | |
| CN104056017A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN106376928A (en) | Method for preparing compound dendrobium officinale health product assisting in reducing blood sugar | |
| CN105920273A (en) | Composition capable of improving and enhancing immunity of organism and preparation method | |
| CN104623061B (en) | A kind of antifatigue | |
| CN114949134A (en) | Composition for improving live yield of threatened abortion patient and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN TIANXIU PLANT TECHNOLOGY DEVELOPMENT CO., L Free format text: FORMER NAME: TIANXIU PLANT SCI-TECH DEVELOPMENT CO., LTD., YUNNAN |
|
| CP03 | Change of name, title or address |
Address after: 650200, incubator management center of Kunming hi tech Zone, Yunnan Province University Science Park, Yunnan overseas student Pioneer Park, No. 139, No. 2, building A2, No. 403, FA Lu, Yunnan Patentee after: Yunnan Tian Xiu plant science and technology development Limited by Share Ltd Address before: 650200, 3 floor, 115 cigarette smoke tower, Kunming Dong Road, Guandu District, Yunnan, China Patentee before: Tianxiu Plant Sci-Tech Development Co., Ltd., Yunnan |
|
| DD01 | Delivery of document by public notice |
Addressee: Cheng Xi Document name: Notification of Passing Examination on Formalities |
|
| CP03 | Change of name, title or address |
Address after: 650106 incubator management center of Kunming high tech Zone, Yunnan Province, No. 403, building A2, phase 2 base, No. 139 Kefa Road, Yunnan University Science Park and Yunnan Overseas Students Pioneer Park Patentee after: Yunnan Tianxiu Plant Technology Co.,Ltd. Address before: 650200 incubator management center of Kunming high tech Zone, Yunnan Province, No. 403, building A2, phase 2 base, No. 139 Kefa Road, Yunnan University Science Park and Yunnan Overseas Students Pioneer Park Patentee before: YUNNAN TIANXIU PLANT TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| CP03 | Change of name, title or address |